Anti-mouse/human DAG1 Recombinant Monoclonal Antibody (XM0057)
Price range: $180.00 through $480.00
Anti-mouse/human DAG1 Recombinant Monoclonal Antibody (XM0057) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library followed by structure-guided affinity optimization. The antibody was validated by ELISA against recombinant epitope-Fc fusion antigen, by Western blot against recombinant MBP-epitope fusion protein, and by Western blot detection of endogenous full-length DAG1 protein.
Also known as: DAG1, Dystroglycan 1, DG, Alpha dystroglycan, and Beta dystroglycan.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-mouse/human DAG1 Recombinant Monoclonal Antibody |
| Antibody ID | XM0057 |
| Target Protein | Dystroglycan 1 |
| Target Protein Short Name | DAG1 |
| UniProt Accession | Q14118 (human), Q62165 (mouse) |
| Molecular Weight | Human: 97.4 kDa; Mouse: 96.9 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Mouse, Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | SMPLILQEEKAPLPPPEYPNQS |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C |
| Research Use | For research use only. Not for diagnostic or therapeutic applications |
Product Background
Dystroglycan 1 (DAG1) is a membrane-associated glycoprotein complex component that links the extracellular matrix to the intracellular cytoskeleton. DAG1 plays critical roles in muscle integrity, cell adhesion, basement membrane organization, neuronal development, and signal transduction.
DAG1 is widely studied in muscular dystrophy, neuromuscular disorders, cancer biology, extracellular matrix signaling, membrane organization, and neurobiology research.
Antibody Development
XM0057 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the DAG1 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot detection of endogenous full-length DAG1 protein
The immunizing epitope sequence is highly conserved between mouse and human DAG1 proteins, supporting cross-reactivity to both species.
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc-only control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to epitope-Fc fusion antigen. Full-length protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while minimal binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length DAG1 protein under reducing conditions.
Validated samples:
- Human HEK293T (293T) cells
- Mouse muscle tissue
- Mouse brain tissue
Observed bands:
- Multiple immunoreactive bands were detected, consistent with known DAG1 processing products, glycosylated forms, cleavage products, or protein-associated complexes.
- Strong bands around approximately 40–60 kDa were observed in multiple samples, consistent with processed dystroglycan-associated species.
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
| Size | 20 ul, 100 ul |
|---|
Related products
